The significant differences in business models between contract manufacturing organizations (CMOs) and biotherapeutic developers translates to very divergent reasons for their increased use of disposable, single-use biomanufacturing devices, according to results from our 9th Annual Report and Survey...
The biomanufacturing industry continues to have problems with downstream operations, as evidenced by the 7 in 10 (71.9%) respondents to our 9th Annual Report and Survey of Biopharmaceutical Manufacturing who report this year that they are seeing at least minor capacity issues due to their downstream...
China continues its remarkable advance last year as the most likely outsourcing destination, edging out stalwarts U.S. and Germany. In our 9th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, research analysis from 302 biopharmaceutical manufacturers in 29 ...
The embracement of single-use applications by the biopharmaceutical
industry is no secret. They now dominate clinical scale manufacturing,
and as the pipeline of new products advances, are now moving into
mainstream commercial bioproduction. However attitudes differ on which
disposable ...
Although relatively few biosimilar products have entered major markets, including no approvals yet in the US, this new class of biopharmaceuticals
is already having a major impact on many (bio)pharmaceutical contract manufacturing organizations (CMOs). As noted below, US and European ...
The biopharmaceutical manufacturing community
continues to find it difficult to staff key
positions, and is turning instead to outsourcing
to fill the gaps. According to preliminary
results from BioPlan Associates’ 13th Annual
Report and Survey of Biopharmaceutical
Manufacturing, hiring trends...